Mylan Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (42)

Latest Posts

About This Stock More About This Stock
Teva Maneuvers To Match 30% Discounts For Generic Copaxone
Article By: Shock Exchange
Friday, October 13, 2017 12:09 PM EDT
Market chatter suggests Mylan is offering 25%-30% discounts on generic Copaxone, and Teva is scrambling to match the discounts. If Teva has to lower Q4 earnings guidance investors could punish the stock.
In this article: TEVA, MYL
Read
Ask Slim Market Week - Friday, Oct 06
Video By: Steve Miller
Friday, October 6, 2017 8:05 PM EDT
The stock market surged most of the week with only a slightly disappointing jobs report able to pull the market down.
In this video: DAL, JWN, LEN, M, UAL, COST, MYL, NFLX, TEVA, TWTR, GPRO
Watch
Pharma Stock Roundup: Mylan Up, Teva Down On Copaxone News, Lawmakers Question Allergan Deal
Article By: Arpita Dutt
Friday, October 6, 2017 10:31 AM EDT
While Mylan and Teva were in the news related to the FDA approval of Mylan’s generic versions of Teva’s top-selling branded drug, Copaxone, Allergan is under fire for its agreement with the Saint Regis Mohawk Tribe for Restasis.
In this article: AGN, TEVA, MYL Also: NVO, SNY, LLY, GSK
Read
Teva Punished By Mylan, Generic Copaxone
Article By: Shock Exchange
Thursday, October 5, 2017 7:54 AM EDT
TEVA fell 14% after MYL was approved for generic Copaxone. A 70% decline in Copaxone sales could be in the cards. Copaxone was 18% of Teva's Q2 revenue. The hit to Teva's EBITDA could be sizeable given rising prices for multiple sclerosis treatments.
In this article: TEVA, MYL
Read
Teva, Momenta Slide After Mylan Gets Earlier Than Expected MS Drug Nod
Article By: The Fly
Wednesday, October 4, 2017 2:52 PM EDT
Shares of Mylan are soaring after the company announced that the Food and Drug Administration had approved its generic version of Teva Pharmaceutical's multiple sclerosis treatment Copaxone.
In this article: MYL Also: PFE, MNTA, TEVA
Read

PARTNER HEADLINES

Latest Tweets for $MYL

No tweets yet!